289 related articles for article (PubMed ID: 31258922)
1. The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS): description of the protocol for a multicentre prospective observational cohort study identifying biomarkers of progressive fibrotic lung disease.
Khan F; Stewart I; Howard L; McKeever TM; Jones S; Hearson G; Braybrooke R; Edwards C; Jenkins G; Saini G
BMJ Open Respir Res; 2019; 6(1):e000439. PubMed ID: 31258922
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of nintedanib in Japanese patients with early-stage idiopathic pulmonary fibrosis: a study protocol for an observational study.
Sakamoto N; Hamada N; Okamoto M; Tobino K; Ichiyasu H; Ishii H; Ichikado K; Morimoto S; Hosogaya N; Mukae H
BMJ Open; 2021 Jun; 11(6):e047249. PubMed ID: 34187824
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study.
Jenkins RG; Simpson JK; Saini G; Bentley JH; Russell AM; Braybrooke R; Molyneaux PL; McKeever TM; Wells AU; Flynn A; Hubbard RB; Leeming DJ; Marshall RP; Karsdal MA; Lukey PT; Maher TM
Lancet Respir Med; 2015 Jun; 3(6):462-72. PubMed ID: 25770676
[TBL] [Abstract][Full Text] [Related]
4. Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort.
Fainberg HP; Oldham JM; Molyneau PL; Allen RJ; Kraven LM; Fahy WA; Porte J; Braybrooke R; Saini G; Karsdal MA; Leeming DJ; Sand JMB; Triguero I; Oballa E; Wells AU; Renzoni E; Wain LV; Noth I; Maher TM; Stewart ID; Jenkins RG
Lancet Digit Health; 2022 Dec; 4(12):e862-e872. PubMed ID: 36333179
[TBL] [Abstract][Full Text] [Related]
5. REMOTE-ILD study: Description of the protocol for a multicentre, 12-month randomised controlled trial to assess the clinical and cost-effectiveness of remote monitoring of spirometry and pulse oximetry in patients with interstitial lung disease.
Barth S; Edwards C; Borton R; Beever D; Adams W; Jenkins G; Pizzo E; Stewart I; Wickremasinghe M
BMJ Open Respir Res; 2024 Feb; 11(1):. PubMed ID: 38418384
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
7. A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease.
Wong AW; Lee TY; Johannson KA; Assayag D; Morisset J; Fell CD; Fisher JH; Shapera S; Gershon AS; Cox G; Halayko AJ; Hambly N; Manganas H; Sadatsafavi M; Wilcox PG; To T; Marcoux V; Khalil N; Kolb M; Ryerson CJ
Respir Res; 2020 Dec; 21(1):322. PubMed ID: 33287805
[TBL] [Abstract][Full Text] [Related]
8. The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study.
Ley B; Newton CA; Arnould I; Elicker BM; Henry TS; Vittinghoff E; Golden JA; Jones KD; Batra K; Torrealba J; Garcia CK; Wolters PJ
Lancet Respir Med; 2017 Aug; 5(8):639-647. PubMed ID: 28648751
[TBL] [Abstract][Full Text] [Related]
9. Serum AGE/RAGEs as potential biomarker in idiopathic pulmonary fibrosis.
Machahua C; Montes-Worboys A; Planas-Cerezales L; Buendia-Flores R; Molina-Molina M; Vicens-Zygmunt V
Respir Res; 2018 Nov; 19(1):215. PubMed ID: 30409203
[TBL] [Abstract][Full Text] [Related]
10. Current possibilities of histopathologic separation of idiopathic pulmonary fibrosis from fibrotic hypersensitivity pneumonitis. How to do it?
Matěj R
Cesk Patol; 2023; 59(1):10-17. PubMed ID: 37072274
[TBL] [Abstract][Full Text] [Related]
11. Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis.
Bowman WS; Newton CA; Linderholm AL; Neely ML; Pugashetti JV; Kaul B; Vo V; Echt GA; Leon W; Shah RJ; Huang Y; Garcia CK; Wolters PJ; Oldham JM
Lancet Respir Med; 2022 Jun; 10(6):593-602. PubMed ID: 35063079
[TBL] [Abstract][Full Text] [Related]
12. Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study.
Veit T; Barnikel M; Crispin A; Kneidinger N; Ceelen F; Arnold P; Munker D; Schmitzer M; Barton J; Schiopu S; Schiller HB; Frankenberger M; Milger K; Behr J; Neurohr C; Leuschner G
Respir Res; 2020 Oct; 21(1):270. PubMed ID: 33076914
[TBL] [Abstract][Full Text] [Related]
13. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study.
Morell F; Villar A; Montero MÁ; Muñoz X; Colby TV; Pipvath S; Cruz MJ; Raghu G
Lancet Respir Med; 2013 Nov; 1(9):685-94. PubMed ID: 24429272
[TBL] [Abstract][Full Text] [Related]
14. Design and rationale of the Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry.
Okuda R; Ogura T; Hisata S; Baba T; Kondoh Y; Suda T; Johkoh T; Iwasawa T; Tomioka H; Bando M; Azuma A; Inoue Y; Arai T; Nakamura Y; Miyamoto A; Miyazaki Y; Chiba H; Ishii H; Hamada N; Terasaki Y; Kuwahira I; Sato S; Kato S; Suzuki T; Sakamoto S; Nishioka Y; Hattori N; Hashimoto N; Morita S; Ichihara N; Miyata H; Hagiwara K; Nukiwa T; Kobayashi K
Respir Investig; 2023 Jan; 61(1):95-102. PubMed ID: 36580379
[TBL] [Abstract][Full Text] [Related]
15. Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial.
Behr J; Neuser P; Prasse A; Kreuter M; Rabe K; Schade-Brittinger C; Wagner J; Günther A
BMC Pulm Med; 2017 Sep; 17(1):122. PubMed ID: 28877715
[TBL] [Abstract][Full Text] [Related]
16. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study.
Walsh SLF; Wells AU; Desai SR; Poletti V; Piciucchi S; Dubini A; Nunes H; Valeyre D; Brillet PY; Kambouchner M; Morais A; Pereira JM; Moura CS; Grutters JC; van den Heuvel DA; van Es HW; van Oosterhout MF; Seldenrijk CA; Bendstrup E; Rasmussen F; Madsen LB; Gooptu B; Pomplun S; Taniguchi H; Fukuoka J; Johkoh T; Nicholson AG; Sayer C; Edmunds L; Jacob J; Kokosi MA; Myers JL; Flaherty KR; Hansell DM
Lancet Respir Med; 2016 Jul; 4(7):557-565. PubMed ID: 27180021
[TBL] [Abstract][Full Text] [Related]
17. Pathologic separation of idiopathic pulmonary fibrosis from fibrotic hypersensitivity pneumonitis.
Wright JL; Churg A; Hague CJ; Wong A; Ryerson CJ
Mod Pathol; 2020 Apr; 33(4):616-625. PubMed ID: 31659276
[TBL] [Abstract][Full Text] [Related]
18. Interstitial Lung Diseases in Developing Countries.
Rivera-Ortega P; Molina-Molina M
Ann Glob Health; 2019 Jan; 85(1):. PubMed ID: 30741505
[TBL] [Abstract][Full Text] [Related]
19. Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases.
Cheng JZ; Wilcox PG; Glaspole I; Corte TJ; Murphy D; Hague CJ; Ryerson CJ
Respirology; 2017 Nov; 22(8):1592-1597. PubMed ID: 28544079
[TBL] [Abstract][Full Text] [Related]
20. Identification of MMP28 as a biomarker for the differential diagnosis of idiopathic pulmonary fibrosis.
Maldonado M; Buendía-Roldán I; Vicens-Zygmunt V; Planas L; Molina-Molina M; Selman M; Pardo A
PLoS One; 2018; 13(9):e0203779. PubMed ID: 30208119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
